期刊文献+

A型肉毒毒素治疗神经源性膀胱的研究进展 被引量:3

Research progress of botulinum toxin A in treatment of neurogenic bladder
暂未订购
导出
摘要 近年来,逼尿肌内注射A型肉毒毒素(botulinum toxin A,BTX-A)治疗神经源性膀胱取得了良好的治疗效果,不仅能改善膀胱功能,而且能减轻下尿路症状,提高患者的生活质量。此外,该项技术具有微创、不良反应轻、可重复注射的优点。目前,国际上对于BTX-A的注射方案并没有达成共识。该文根据近年来的研究成果,对BTX-A的作用机制、类型、注射方案、治疗效果、影响疗效的因素以及不良反应和禁忌证做一综述,为BTX-A在临床中的应用提供参考。 In recent years, intradetrusor injection of botulinum toxin A(BTX-A) has achieved satisfactory therapeutic effects on the treatment of neurogenic bladder, improving the bladder function and reducing the lower urinary tract symptoms while improving patients’ quality of life. In addition, this therapy has advantages including minimal invasiveness, mild side effects, and allowing repeated injections. At present, there is no international consensus on the injection plan for BTX-A. Therefore, based on the recent clinical research results, this paper reviews the mechanism of action, types, usage, therapeutic effects, influencing factors, as well as adverse reactions and contraindications of BTX-A, in an attempt to provide evidence for its clinical application.
作者 张霖 陈忠 ZHANG Lin;CHEN Zhong(Department of Urology,Shanghai Sixth People's Hospital,Shanghai Jiao Tong University,Shanghai 200233,China)
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2022年第1期113-118,共6页 Journal of Shanghai Jiao tong University:Medical Science
基金 上海市卫生和计划生育委员会面上项目(20174011)。
关键词 A型肉毒毒素 神经源性膀胱 神经源性逼尿肌过度活动 botulinum toxin A neurogenic bladder neurogenic detrusor overactivity
  • 相关文献

参考文献4

二级参考文献51

  • 1于建敏,王艳,宋红平.A型肉毒毒素加强法治疗面肌痉挛[J].中国神经免疫学和神经病学杂志,2003,10(3):190-190. 被引量:9
  • 2廖利民,李东,熊宗胜,韩春生,黄悦,史文博.经尿道膀胱壁A型肉毒毒素注射治疗脊髓损伤患者逼尿肌反射亢进及神经原性尿失禁[J].中华泌尿外科杂志,2004,25(9):596-598. 被引量:40
  • 3廖利民,付光,史文博,熊宗胜,鞠彦合,吴娟,李东,韩春生,梁文利.尿道括约肌内注射A型肉毒毒素治疗脊髓损伤患者逼尿肌-括约肌协同失调的临床观察[J].中国脊柱脊髓杂志,2006,16(6):409-412. 被引量:16
  • 4Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function:Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
  • 5Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschom S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-14.
  • 6Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2010;2:11-24.
  • 7Getsios D, El-Hadi W, Caro I, Caro JJ. Pharmacological management of overactive bladder: A systematic and critical review of published economic evaluations. Pharmacoeconomics 2005;23:995-1006.
  • 8Chappie CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55:33-46.
  • 9Garely AD, Burrows LJ. Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 2002;3:827-33.
  • 10Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature. Int J Clin Pract 2011;65:567-85.

共引文献47

同被引文献68

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部